Moores Receives $1M from Pfizer for Early Cancer Detection
|
This donation will facilitate the Early Detection and Prevention Initiative at Moores, which will expand access to essential screenings and apply leading-edge diagnostics to improve community outcomes. Learn More>>
|
New American Association for the Advancement of Science (AAAS) Fellow
|
Moores Member Zea Borok, MD has been elected an AAAS Fellow for her contributions to improving patient care and training future healthcare leaders. Learn More>>
|
The PRECEDE Study for Pancreatic Cancer Survival
|
PRECEDE, led by Moores Director Diane Simeone, MD, will improve pancreatic cancer survival rates within the next decade through early detection, innovative research, and collaborative expertise. Learn More>>
|
Moores Member Named Fellow of the American Society of Clinical Oncology (FASCO)
|
Kudos to Moores Member and Solid Tumor Therapeutics Research Program Co-Leader Sandip Patel, MD for earning the FASCO distinction for his volunteer service, engagement, and dedication to cancer care and prevention. Learn More>>
|
|
|
17th Annual Salk Mechanisms and Models of Cancer Symposium
|
Registration is now open for this series of thought-provoking lectures from leading experts. Attendees will engage cutting-edge research, exchange ideas, and inspire future innovations. Learn More and Register>>
|
|
|
The Researcher Spotlight is designed to help you connect with fellow researchers, gain insights into their diverse projects, and discover the paths that led them to their current roles. Uncover a personal touch to their professional achievements, showcasing the varied perspectives within our cancer research community.
|
Jason Sicklick, MD, FACS, is an internationally recognized surgical oncologist who specializes in treating gastrointestinal stromal tumors (GIST), abdominal/retroperitoneal sarcomas, and liver tumors (primary and metastatic). He advances cancer care through innovation and collaboration, co-leading the Sarcoma Disease Team at UC San Diego Health and serving on national committees that shape best practices for rare cancers. A professor at UC San Diego School of Medicine, he researches precision medicine, GIST development, and drug resistance while co-leading the Structural and Functional Genomics research program at Moores.
|
|
|
| Reducing clinical trial eligibility barriers for patients with MDS: An icMDS position statement
|
Rafael Bejar, MD, PhD (Hematologic Malignancies)
|
|
|
| Inhibition of human-HPV hybrid ecDNA enhancers reduces oncogene expression and tumor growth in oropharyngeal cancer
|
Kathleen M. Fisch, PhD (Structural and Functional Genomics [SFG]), Vineet Bafna, PhD (SFG), and Joseph Califano, MD (SFG)
|
|
|
| Utilizing two electrokinetic techniques on a single device for detection of extracellular vesicle-associated protease activity
|
Michael Heller, PhD (Hematologic Malignancies)
|
|
|
CLINICAL TRIALS OFFICE (CTO)
|
NRG-HN014: Randomized Phase III Trial of Perioperative Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
PI: Loren Mell, MD
NCT ID: NCT06568172
10592: A Randomized Phase II Study of ATR Inhibition in Advanced PD(L)1 Refractory Merkel Cell Carcinoma: The MATRiX Trial
PI: Soo Park, MD
NCT ID: NCT05947500
EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
PI: Loren Mell, MD
NCT ID: NCT04671667
|
|
|
|
